Conceptus to Hold Third Quarter Financial Results Conference Call November 8, 2004.

SAN CARLOS, Calif. -- Conceptus, Inc. (Nasdaq:CPTS), developer of the non-incisional permanent birth control procedure Essure(R), today announced that the Company will release 2004 third quarter financial results on Monday, November 8, 2004 after the close of market. Management will host an investment-community conference call beginning at 4:30 p.m. Eastern Time on November 8, 2004 to discuss the results and to answer questions. E[acute accent]To participate in the live call by telephone, please dial [phone] from the U.S., or for international callers, please dial [phone]. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, www.conceptus.com. A replay will be available on the website for 14 days. E[acute accent]A telephone replay will be available from 7:30 p.m. Eastern Time November 8, 2004 through 11:59 p.m. Eastern Time on November 10, 2004 by dialing [phone] (domestic) or [phone] (international) and entering conference ID number 1694299.

E[acute accent]About Essure

E[acute accent]The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. Essure is 99.80% effective after three years of follow-up.

E[acute accent]About Conceptus

E[acute accent]Conceptus, Inc. manufactures and markets Essure, an innovative medical device and procedure, designed to provide a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide. The availability of Essure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually. E[acute accent]Additional information about the Essure procedure is available at www.Essure.com or by calling the Essure Information line at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.

E[acute accent]Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Projected net sales and net loss for the third and fourth quarters of 2004, the success of new marketing programs, clinical efficacy of and market demand for our product and receipt of permanent reimbursement codes, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as decisions by insurance companies, delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.